Aripiprazole Tablet
Product Images NDC 67877-433

16 FDA label images from Ascend Laboratories, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 67877-433). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Aripiprazole Structure (Aripiprazole Fig8)
Chemical structure of aripiprazole showing its molecular arrangement including chlorinated phenyl, piperazine ring, and quinolinone components.*
FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)
A scatter plot showing the fold change and 90% confidence intervals of Aripiprazole pharmacokinetic parameters AUC and Cmax relative to reference without interacting drugs. The chart compares effects of various inhibitors and inducers including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs such as valproate, lithium, and lorazepam.*
FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)
A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing the relative change in AUC and Cmax values compared to a reference without interacting drug. The chart includes data points for various inhibitors, inducers, gastric acid blockers, and other drugs affecting Aripiprazole metabolism, with error bars indicating 90% confidence intervals.*
FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)
A chart depicting fold changes and 90% confidence intervals for various pharmacokinetic parameters (DMVDRP, AUC, Cmax, INR) of drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram, showing changes relative to a reference without interacting drug.*
FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)
A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing changes in AUC and Cmax related to various factors: CYP2D6 metabolism status, gender, age groups, hepatic impairment severity, and severe renal impairment. The horizontal axis represents change relative to reference values, with data points and confidence intervals for each factor comparison.*
FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)
A pharmacokinetic chart showing fold change and 90% confidence intervals of Dehydro-Aripiprazole relative to reference. The chart compares exposure metrics (AUC and Cmax) for multiple factors including CYP2D6 metabolism status, gender, age groups, hepatic impairment severity, and severe renal impairment.*
FDA Label Image

Aripiprazole-graph-a (Aripiprazole Graph A)

Aripiprazole-graph-a (Aripiprazole Graph A)
A Kaplan-Meier survival curve graph showing the proportion of subjects with relapse over 182 days from randomization for Aripiprazole versus placebo. The graph compares relapse rates, with Aripiprazole represented by a solid line showing a lower relapse proportion than placebo's dashed line. The number of subjects at risk is listed below the x-axis over time.*
FDA Label Image

Aripiprazole-fig-16-a (Aripiprazole Fig 16 A)

Aripiprazole-fig-16-a (Aripiprazole Fig 16 A)
A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization for Aripiprazole versus placebo. The solid line represents Aripiprazole, showing a lower relapse proportion over time compared to the dashed line for placebo. Subject counts at risk are displayed below the x-axis for both groups across multiple time points up to 182 days.*
FDA Label Image

Aripiprazole-fig-17-a (Aripiprazole Fig 17 A)

Aripiprazole-fig-17-a (Aripiprazole Fig 17 A)
A line graph depicting the proportion of relapse over days from randomization comparing Aripiprazole and placebo groups. The x-axis represents days from randomization up to 364 days, and the y-axis represents the proportion with relapse, ranging from 0 to 1. Two lines show relapse trends: one solid line for Aripiprazole and one dashed line for placebo, with subject numbers at risk indicated below the x-axis for both groups at multiple time points.*
FDA Label Image

Aripiprazole-fig-18 (Aripiprazole Fig 18)

Aripiprazole-fig-18 (Aripiprazole Fig 18)
A line graph depicting the change in YGTSS total TIC score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole Low dose, Aripiprazole High dose, and Placebo, showing the least-squares mean change on the Y-axis and weeks of treatment on the X-axis.*
FDA Label Image

Aripiprazole-fig1b (Aripiprazole Fig1b)

Aripiprazole-fig1b (Aripiprazole Fig1b)
Label for Aripiprazole Tablets, USP 2 mg by Ascend Laboratories, LLC. The oral tablet package contains 30 tablets. The label includes storage instructions, manufacturer details (Alkem Laboratories Ltd., India), NDC 67877-430-03, and advises dispensing the enclosed medication guide with each patient. Marked Rx only.*
FDA Label Image

Aripiprazole-fig2b (Aripiprazole Fig2b)

Aripiprazole-fig2b (Aripiprazole Fig2b)
Label for Aripiprazole Tablets USP 5 mg by Ascend Laboratories, LLC. The label includes dosage strength, quantity of 100 tablets, NDC 67877-431-01, storage instructions, and manufacturer information (Alkem Laboratories Ltd., India). It also notes dispensing a medication guide to each patient and is marked Rx Only.*
FDA Label Image

Aripiprazole-fig3b (Aripiprazole Fig3b)

Aripiprazole-fig3b (Aripiprazole Fig3b)
Aripiprazole Tablets USP 10 mg oral tablets label from Ascend Laboratories, LLC, showing a package size of 500 tablets. The label includes storage instructions, a barcode, and directs users to a medication guide for dosage and usage details. Manufactured by Alkem Laboratories, India, and distributed by Ascend Laboratories, New Jersey.*
FDA Label Image

Aripiprazole-fig4b (Aripiprazole Fig4b)

Aripiprazole-fig4b (Aripiprazole Fig4b)
Label for Aripiprazole Tablets USP 15 mg oral tablets by Ascend Laboratories, LLC. The label includes dosage guidelines, storage instructions, and safety notices. Packaging contains 30 tablets and indicates prescription use only. The label also notes manufacturing by Alkem Laboratories, Ltd, Mumbai, India, and distribution by Ascend Laboratories, LLC, Bedminster, NJ.*
FDA Label Image

Aripiprazole-fig5b (Aripiprazole Fig5b)

Aripiprazole-fig5b (Aripiprazole Fig5b)
Label for Aripiprazole Tablets USP 20 mg by Ascend Laboratories, LLC. The label includes dosage instructions referencing a package insert, storage conditions at controlled room temperature, and warnings to keep out of reach of children. It states the product contains 100 tablets, is Rx only, and provides manufacturer and distributor information. The label also includes a barcode and an area marked for UV varnish.*
FDA Label Image

Aripiprazole-fig6b (Aripiprazole Fig6b)

Aripiprazole-fig6b (Aripiprazole Fig6b)
Label for Aripiprazole Tablets, USP 30 mg, oral tablets by Ascend Laboratories, LLC. The label includes the NDC 67877-435-05 and specifies a quantity of 500 tablets. It includes storage instructions, manufacturer and distributor details, and advises dispensing the enclosed Medication Guide with each prescription.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.